Pillar guide
Ipamorelin: UK research-tier pillar on the cleanest ghrelin mimetic
oliver-mackman · Editorial director · Best Business Loans Ltd (16833937)
Published Tue May 19 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Hero capsule
Ipamorelin is a synthetic pentapeptide ghrelin-receptor (GHSR) mimetic developed in the late 1990s as part of a structural search for growth-hormone secretagogues with a cleaner side-effect profile than the GHRP family. In the preclinical literature it is consistently described as the most selective compound in its class, producing dose-dependent growth hormone release in rodent and ex vivo pituitary models with minimal accompanying elevation of cortisol, adrenocorticotropic hormone, prolactin, or aldosterone, and without the appetite stimulation reported for GHRP-2, GHRP-6, and Hexarelin. UK sale is research-tier only, with no marketing authorisation as a medicine. WADA-prohibited under the S2 secretagogue category in and out of competition.
What it is
Ipamorelin is a synthetic peptide first described by Raun and colleagues at Novo Nordisk in 1998. The published structure is a pentapeptide amide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2. Two of the five residues are non-natural amino acids: aminoisobutyric acid (Aib) at the N-terminus and D-2-naphthylalanine (D-2-Nal) at position three. The non-natural residues are the source of the compound’s enzymatic stability and selectivity. Calculated molecular weight is approximately 711.86 daltons.
The compound binds the growth hormone secretagogue receptor type 1a, also written GHSR or GHSR-1a, on pituitary somatotrophs and at sites in the hypothalamic arcuate nucleus. GHSR is the receptor for endogenous ghrelin, the gut-derived octanoylated peptide hormone first characterised by Kojima and colleagues in 1999. Ghrelin itself signals through GHSR to promote growth hormone release, appetite, gastric motility, and a cluster of downstream metabolic effects. Synthetic ghrelin mimetics activate the receptor without acting on the upstream acyl-modification machinery that ghrelin depends on, and without the broader peripheral receptor distribution that gives ghrelin its appetite and motility footprint.
What makes Ipamorelin pharmacologically distinct from ghrelin itself is selectivity at the receptor level. Raun and colleagues reported that the compound produces growth hormone release comparable in magnitude to GHRP-6 in pituitary cell culture, but without the cortisol and prolactin elevation that characterises GHRP-6 and without the appetite signal that characterises ghrelin. The selectivity is structural. The Aib residue and the D-amino acids stabilise a conformation that engages the receptor pocket responsible for the GH-release signal more efficiently than the receptor states associated with feeding behaviour and corticotrope activation.
In research nomenclature Ipamorelin is described as a growth hormone secretagogue, a ghrelin mimetic, and a GHSR agonist. The three terms refer to the same molecule from three different vantage points: functional output, biological inspiration, and receptor mechanism.
What the preclinical literature shows
The published preclinical record on Ipamorelin runs to several dozen papers, concentrated in the period from 1998 to the mid-2000s and with intermittent publications since. Six themes dominate the literature.
First, dose-dependent growth hormone release in rodents. Raun et al. (1998, European Journal of Endocrinology, PMID 9849822) reported plasma growth hormone increases in pentobarbital-anaesthetised rats following intravenous Ipamorelin administration, with potency comparable to GHRP-6 on a molar basis and a maximum response in the same order of magnitude as observed for the saturating GHRP family in the same model. Follow-up work by the same group confirmed dose-response curves in conscious rats and in swine, with growth hormone peaks observed within minutes of intravenous administration and a return to baseline within roughly an hour, consistent with the compound’s reported short plasma half-life.
Second, minimal cortisol and adrenocorticotropic hormone elevation. The same Raun papers, and an early human safety study by Gobburu and colleagues (1999, Clinical Pharmacology and Therapeutics, PMID 10579482), reported that doses producing clear growth hormone responses did not produce detectable changes in plasma cortisol or adrenocorticotropic hormone. By contrast, equipotent doses of GHRP-6 and GHRP-2 in the same experimental systems produced measurable corticotrope activation. This pharmacological separation is the headline finding of the Ipamorelin literature.
Third, no appetite stimulation. Whereas ghrelin itself, and to a lesser extent GHRP-6, produce measurable increases in food intake in rodent models within minutes of administration, Ipamorelin in the published rodent work does not produce a detectable feeding response at growth-hormone-effective doses. The receptor selectivity that spares the corticotrope appears to spare the feeding circuit as well, although the underlying receptor pharmacology behind this dissociation is not fully resolved in the public literature.
Fourth, no prolactin elevation. Hexarelin and GHRP-2 in published comparisons produce modest prolactin release alongside the growth hormone signal. Ipamorelin in the same models does not. Johansen and colleagues (1999, Journal of Endocrinology, PMID 10444163) reported the dissociation in a head-to-head pituitary cell culture comparison.
Fifth, bone and connective tissue work. Svensson and colleagues (2000, Growth Hormone and IGF Research, PMID 11167194) published a rat fracture-healing study using Ipamorelin and reported improved bone mineral density and callus formation versus control. The work is preclinical, small, and not replicated in human surgical populations. We list it because it is one of the most commonly cited Ipamorelin papers in retailer marketing and we want researchers reading our material to know exactly what was, and was not, demonstrated.
Sixth, gastrointestinal motility. A small ileus-prevention literature exists in postoperative surgical rat and pig models, summarised by Greenwood-Van Meerveld and colleagues (2011, Neurogastroenterology and Motility, PMID 21794034). The compound was investigated by Helsinn Therapeutics under the development name HP-3070 for postoperative ileus through the early 2010s. Development was discontinued. The motility effect appears separable from the growth hormone effect and depends on peripheral GHSR populations in enteric tissue.
Additional citations that appear in serious researcher reading lists include the comparative ghrelin-mimetic pharmacology review by Smith and colleagues (1997, Endocrine Reviews, PMID 9335404), which predates Ipamorelin but situates the receptor pharmacology; the structural conformation analysis by Pedersen and colleagues (2009, Biochemical Pharmacology, PMID 19094967); and the Helsinn-led phase II postoperative ileus trial summary (Beck et al., 2014, PMID 24667971), which is one of the few human-data Ipamorelin papers in the public record.
Across the published record, the consistent signal is selective GH release with a cleaner off-target profile than the GHRP comparators tested in the same experimental systems. The literature does not establish efficacy for any human therapeutic indication, and we will return to that point below.
Comparison with other ghrelin mimetics
Ipamorelin sits inside a small structural family of synthetic ghrelin-receptor agonists. Four compounds dominate the published research lane: GHRP-6, GHRP-2, Hexarelin, and Ipamorelin itself. A fifth, Ibutamoren (MK-677), is a non-peptide small-molecule GHSR agonist developed by Merck and sits adjacent to the family but is not a peptide.
GHRP-6 is the first-generation ghrelin mimetic, a synthetic hexapeptide developed by Bowers and colleagues in the late 1980s before ghrelin itself was discovered. It produces strong growth hormone release in preclinical and early human work but is consistently associated with measurable cortisol, prolactin, and appetite signals. It remains a common reference compound in published comparisons.
GHRP-2 is a second-generation hexapeptide with greater potency than GHRP-6 and a partially cleaner off-target profile, but still measurable cortisol and prolactin elevation in head-to-head preclinical work. It is sometimes preferred over GHRP-6 in research contexts where appetite stimulation is a confound, but Ipamorelin is preferred over both where the research question is selectively about growth hormone biology.
Hexarelin is a third hexapeptide in the same family, structurally similar to GHRP-6 but with greater potency and, distinctively, additional reported activity at the CD36 receptor in cardiac tissue. Hexarelin produces strong growth hormone release but the highest cortisol and prolactin signals of the four named compounds. Receptor desensitisation with repeated dosing is more pronounced than in the Ipamorelin literature.
Ipamorelin is the youngest of the four and was developed specifically to address the off-target problem. The pentapeptide structure with Aib and D-2-Nal residues is the result of a structural search for the cleanest possible GHSR-mediated growth hormone signal. The published comparative work places Ipamorelin at the bottom of the cortisol-elevation list and the appetite-elevation list, with growth hormone release potency comparable to GHRP-6 and somewhat below GHRP-2 on a molar basis.
For researchers selecting a ghrelin mimetic for a study where the question is specifically about growth hormone biology, and where confounds from corticotrope activation, prolactin release, or feeding behaviour would compromise the experimental design, Ipamorelin is the conventional choice. Where the research question is specifically about appetite, or about the CD36 receptor in cardiac tissue, GHRP-6 or Hexarelin remain the appropriate tools. Compound selection should be driven by the research question, not by retailer marketing.
What the literature does NOT show
There are several things the published Ipamorelin literature does not establish and which should not be inferred from the preclinical record.
It does not establish efficacy in adult-onset growth hormone deficiency. The compound has never proceeded through phase III trials in any growth hormone deficiency indication. Helsinn Therapeutics ran a phase II programme in postoperative ileus, not in growth hormone deficiency, and the programme was discontinued. There is no approved human use, anywhere.
It does not establish a clinical dose-response curve. The handful of human pharmacokinetic and tolerability papers describe single-dose intravenous administration in healthy volunteers and surgical patients. They do not establish a chronic dosing schedule, do not characterise tachyphylaxis or receptor desensitisation in humans, and do not characterise dose-response for any clinical endpoint. The dose figures circulated in non-academic peptide forums are extrapolations from animal work, not validated human protocols.
It does not establish efficacy or safety for body composition, athletic performance, anti-ageing, or sleep-architecture endpoints. These are common claims in retailer marketing and online forums. The published literature does not contain controlled human trials supporting any of them. Researchers should treat such claims as marketing-tier, not literature-tier.
It does not establish IGF-1 dynamics over chronic use in humans. Whether sustained Ipamorelin administration produces sustained IGF-1 elevation, transient elevation followed by receptor desensitisation, or no meaningful IGF-1 signal in humans is not resolved by the public record.
It does not establish injection-site, immunogenicity, or long-term safety profiles in humans. The phase II ileus work involved short courses in surgical settings and was discontinued before producing the kind of long-duration safety data that would inform any chronic-use risk assessment.
Honest framing of what the literature does and does not show is part of the editorial baseline at PeptideClear. Researchers reading retailer copy, forum threads, or clinic marketing material should expect to encounter claims well beyond what the published record supports.
UK regulatory status
Ipamorelin’s UK status involves four overlapping regulatory frameworks and requires care to summarise accurately.
Under the Human Medicines Regulations 2012, Ipamorelin has no UK marketing authorisation. The Medicines and Healthcare products Regulatory Agency (MHRA) has not licensed Ipamorelin for any indication, and no Marketing Authorisation Holder lists the compound in any licensed product. It is therefore unlawful to supply Ipamorelin in the UK as a medicine for human use or to make therapeutic claims for it. Retailer copy that frames Ipamorelin as a treatment for any condition is making a regulatory error.
Under the Misuse of Drugs Act 1971, Ipamorelin is not a controlled drug. It is not listed in any of the schedules and not included by class within any of the schedules. Possession is not a criminal offence under the Act.
Under the Psychoactive Substances Act 2016, Ipamorelin is not scheduled. The Act explicitly excludes substances regulated by the medicines framework, and supply for research-only purposes outside the medicines framework is the route most UK retailers operate under.
Under the World Anti-Doping Agency (WADA) Prohibited List, Ipamorelin is explicitly prohibited at all times, in and out of competition, under section S2.2 (Growth Hormone Secretagogues). Possession or use by an athlete subject to anti-doping jurisdiction is an anti-doping rule violation regardless of route of administration or competition period. UK Anti-Doping (UKAD) enforces the WADA list in the United Kingdom and has historically pursued GHSR-active compounds in athlete cases. Researchers working with athletes, or competitive athletes themselves, should treat this as a hard line.
The net regulatory position is that UK sale of Ipamorelin for in vitro research, labelled clearly as not for human consumption and accompanied by a Certificate of Analysis, occurs lawfully through specialist research-peptide retailers. Sale for human use, sale with therapeutic claims, and any clinical or athletic use sit outside the lawful research-use frame and carry distinct regulatory exposure.
For the broader picture of how WADA’s prohibited list interacts with the UK research-peptide market, see our explainer at /explained/wada-prohibited-list-peptides/. For the meaning of research-use-only labelling in UK consumer law, see /explained/research-use-only/.
Where UK researchers source Ipamorelin
Ipamorelin is widely stocked by UK research-peptide retailers. The compound sits in the GH-secretagogue lane, which carries higher counterfeit risk than the healing-peptide lane (BPC-157, TB-500) and substantially higher counterfeit risk than the cosmetic-peptide lane (GHK-Cu, Matrixyl). Certificate of Analysis (CoA) documentation is therefore more material in this category than in the others, and our CoA Trust Index is the appropriate filter for retailer selection.
Five UK retailers stock Ipamorelin at the time of writing. CoA tier classifications follow the PeptideClear methodology described at /methodology/research-peptides/.
Direct Sarms UK carries Ipamorelin in a single vial size with a third-party HPLC CoA available on the product page. CoA Trust Index: Tier 1. UK-based fulfilment from a Manchester-area warehouse. Established reputation in the UK research-peptide community.
Pure Peptides UK stocks Ipamorelin in multiple vial sizes and bundles the compound into the named Hulk Stack with CJC-1295. CoA documentation is on a per-batch basis. CoA Trust Index: Tier 1. UK fulfilment from the South East.
My Peptides lists Ipamorelin as a standalone item and within a GH-secretagogue bundle. Per-batch CoA available on request rather than on the product page directly. CoA Trust Index: Tier 2. UK fulfilment.
Research Peptides UK carries Ipamorelin and CJC-1295 with consistent CoA presentation across both products. CoA Trust Index: Tier 1.
Reagent lists Ipamorelin in a research-tier catalogue alongside the wider ghrelin-mimetic family including GHRP-2, GHRP-6, and Hexarelin. CoA Trust Index: Tier 2.
For the GH-secretagogue category specifically we would recommend Tier 1 retailers over Tier 2, given the higher counterfeit risk in this lane. Researchers comparing retailers should look for HPLC purity figures in the high 98 to 99 percent range, mass spectrometry confirmation of the expected molecular weight, and a batch identifier traceable to the vial received. Our explainer at /explained/hplc-purity/ details what HPLC purity figures mean and the limits of what they confirm.
Common stacks
Two named stacks dominate the Ipamorelin literature in retailer-facing material and the wider researcher discussion.
The first is the Hulk Stack, which pairs Ipamorelin with the long-acting GHRH analogue CJC-1295. The pharmacological rationale is dual-pathway growth hormone release. Ipamorelin activates the ghrelin receptor on pituitary somatotrophs; CJC-1295 activates the GHRH receptor on the same cells. Preclinical work and small human pharmacokinetic studies suggest the two pathways produce additive growth hormone release rather than competitive interference. CJC-1295 is available in a with-DAC variant (Drug Affinity Complex modification, half-life approximately eight days) and a without-DAC variant (half-life approximately thirty minutes). The without-DAC variant is the more common Hulk Stack pairing in research contexts because it preserves the natural pulsatile growth hormone profile that Ipamorelin’s short half-life is designed to respect. Full editorial detail at /stacks/hulk/.
The second is the GH Stack, which is the generic class name for any GH-secretagogue combination pairing a GHRH-pathway compound with a ghrelin-pathway compound. The Hulk Stack is the canonical GH Stack but the category extends to Tesamorelin plus Ipamorelin, Sermorelin plus Ipamorelin, and other less common pairings. Full editorial detail and pairing rationale at /stacks/gh-stack/.
Neither stack is associated with a validated human protocol and neither carries any clinical or therapeutic endorsement. The stacks are research configurations described in the published preclinical work and in retailer-facing material, presented here for researcher orientation rather than as use guidance.
FAQ
Q: How significant is the counterfeit risk in the GH-secretagogue category compared with other research peptides?
A: Materially higher than the healing-peptide or cosmetic-peptide lanes. The GH-secretagogue category includes Ipamorelin, the GHRP family, Hexarelin, Sermorelin, CJC-1295, and Tesamorelin. The published independent purity-testing work on the UK research-peptide market is limited, but where it exists it consistently identifies higher rates of off-spec product in the GH-secretagogue lane than in BPC-157 or TB-500. The structural complexity of these peptides, the higher commercial price point, and the higher researcher demand combine to make the category a more frequent counterfeit target. Tier 1 CoA documentation, batch-traceable, third-party HPLC and mass spectrometry tested, is the appropriate baseline for this lane.
Q: Why is Ipamorelin paired with CJC-1295 specifically?
A: Because the two compounds target different receptors on the same cells. Ipamorelin activates the GHSR ghrelin receptor; CJC-1295 activates the GHRH receptor. The two receptors converge on growth hormone release through distinct intracellular signalling pathways, and preclinical work shows additive rather than competitive output. Pairing a ghrelin-pathway compound with a GHRH-pathway compound is the standard configuration for any GH-secretagogue research stack. CJC-1295 is the most commonly used GHRH-pathway partner because of established research familiarity, but Sermorelin and Tesamorelin are pharmacologically valid alternatives.
Q: What is the published half-life of Ipamorelin?
A: Approximately two hours in the limited human pharmacokinetic record, with the caveat that the human data is thin. Animal model half-lives are reported as shorter, in the range of tens of minutes. The short half-life is the pharmacological basis for the compound’s reputation as preserving natural pulsatile growth hormone release patterns, in contrast with longer-acting agents that produce sustained elevation outside the physiological rhythm. Our explainer on the meaning and limits of half-life figures in peptide research is at /explained/peptide-half-life/.
Q: Is Ipamorelin available on the NHS or private prescription in the UK?
A: No. Ipamorelin has no UK marketing authorisation in any product. It is not available through the NHS, not available on private prescription, and not licensed as a medicine in any UK preparation. Sale occurs only through research-peptide retailers under research-use-only framing.
Q: How does the WADA prohibition apply to researchers who are not athletes?
A: The WADA list does not apply to non-athletes as a matter of doping law. It applies to athletes subject to anti-doping jurisdiction, which in the UK includes those competing under UKAD-regulated bodies and most international federations. Researchers working with athletes, sports scientists in athlete-facing settings, and competitive athletes themselves should treat the WADA prohibition as decisive. The WADA listing is also relevant context for the regulatory category the compound occupies and is part of why no UK clinical pathway exists for it.
Q: What CoA documentation should I expect on a Tier 1 Ipamorelin product?
A: HPLC purity figure in the high 98 to 99 percent range with the chromatogram visible, mass spectrometry confirmation of the expected molecular weight of approximately 711.86 daltons, a batch identifier traceable to the vial received, and a testing date within a reasonable window of the batch production date. Some Tier 1 retailers also provide endotoxin and microbial testing for reconstitution-grade preparations. Our explainer at /explained/coa-certificate-of-analysis/ details what a complete CoA looks like and what individual line items confirm.
Outstanding research questions
Despite three decades of preclinical work, the public literature on Ipamorelin leaves several substantive questions unresolved.
The first is the long-term receptor pharmacology in humans. Whether chronic GHSR activation through Ipamorelin produces meaningful receptor desensitisation or tachyphylaxis in humans, on what timescale, and with what implications for sustained growth hormone or IGF-1 output, is not characterised. The rodent work suggests less desensitisation than for the GHRP family, but the human data is too thin to confirm or refute the rodent pattern.
The second is the relationship between pulsatile growth hormone release and downstream physiological endpoints. The pharmacological case for Ipamorelin over longer-acting GHRH analogues rests on the value of preserving natural pulsatile growth hormone patterns rather than producing sustained elevation. Whether pulsatile versus sustained release patterns translate into different downstream physiological outcomes in humans is an open question.
The third is the appropriate human dose range. The figures that circulate in non-academic settings are extrapolations from rodent work and from the limited human single-dose pharmacokinetic studies. A properly characterised human dose-response curve for any clinically meaningful endpoint does not exist in the published literature.
The fourth is the comparative pharmacology of Ipamorelin against ghrelin itself in human research. The selectivity advantages over GHRP-6 and GHRP-2 are well documented. The full comparison against the endogenous ligand is less well characterised, particularly in chronic-administration settings.
The fifth is the role, if any, of peripheral GHSR populations in any physiological effects observed beyond growth hormone release. The discontinued postoperative ileus programme suggested a peripheral motility signal separable from the growth hormone signal, but the underlying receptor pharmacology is incompletely worked out.
Researchers entering this lane should expect to encounter retailer copy and forum discussion that goes well beyond what the published literature supports. The honest summary is that Ipamorelin is the cleanest tool in the ghrelin-mimetic category for studying selective growth hormone biology in preclinical systems, and that essentially everything beyond that selective preclinical use is research speculation or marketing.
This article is editorial research orientation only. Ipamorelin is not a licensed medicine in the United Kingdom. No therapeutic claim is made. WADA-prohibited under section S2. Research use only. For methodology see /methodology/research-peptides/.
Author: Oliver Mackman. Editorial review: PeptideClear research desk. Published 19 May 2026.